ReFacto AF, also known as Antihemophilic Factor (Recombinant), is a genetically engineered version of factor VIII, a protein that is essential for blood clotting. This medication is used in the treatment and management of hemophilia A, a genetic disorder characterized by the inability of blood to clot properly due to the deficiency of factor VIII. ReFacto AF works by replacing the missing or defective factor VIII, thereby helping to control and prevent bleeding episodes. It is administered through intravenous injection and is used both on a schedule to prevent bleeding episodes (prophylaxis) and to treat them when they occur. This medicine is crucial for individuals with hemophilia A, improving their quality of life by managing symptoms and reducing the risk of bleeding complications.